Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Non-Current Debt (2019 - 2025)

SRx Health Solutions' Non-Current Debt history spans 7 years, with the latest figure at $1.9 million for Q2 2025.

  • For Q2 2025, Non-Current Debt changed N/A year-over-year to $1.9 million; the TTM value through Jun 2025 reached $1.9 million, changed N/A, while the annual FY2023 figure was $5.0 million, 56.31% down from the prior year.
  • Non-Current Debt reached $1.9 million in Q2 2025 per SRXH's latest filing, up from $696000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $11.5 million in Q1 2023 to a low of $696000.0 in Q3 2024.
  • Average Non-Current Debt over 5 years is $5.4 million, with a median of $4.8 million recorded in 2021.
  • Peak YoY movement for Non-Current Debt: skyrocketed 151.02% in 2022, then crashed 74.36% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $4.6 million in 2021, then surged by 151.02% to $11.4 million in 2022, then crashed by 56.31% to $5.0 million in 2023, then tumbled by 86.08% to $696000.0 in 2024, then surged by 173.42% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for SRXH's Non-Current Debt are $1.9 million (Q2 2025), $696000.0 (Q3 2024), and $5.0 million (Q4 2023).